Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 30 of 146 results for copd

  1. Dupilumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils ID6235

    In development Reference number: GID-TA11246 Expected publication date:  11 February 2026

    Technology appraisal guidance
    In development

  2. Suspected acute respiratory infection in over 16s: assessment at first presentation and initial management (NG237)

    This guideline covers assessment of people aged 16 and over with symptoms and signs of acute respiratory infection (bacterial or viral) at first remote or in-person contact with NHS services. It also covers the initial management of any infections. It aims to support healthcare practitioners in making sure that people’s treatment follows the best care pathway. It forms part of a suite of work on virtual wards being undertaken by NICE.

    NICE guideline
    Last updated
    2 September 2025
    View recommendations

    Sections for NG237

  3. myAIRVO2 for the treatment of chronic obstructive pulmonary disease (MIB161)

    NICE has developed a medtech innovation briefing (MIB) on myAIRVO2 for the treatment of chronic obstructive pulmonary disease .

    Medtech innovation briefing
    Published
    1 October 2018

  4. FreeO2 automatic oxygen titration for chronic obstructive pulmonary disease and respiratory distress syndrome (MIB281)

    NICE has developed a medtech innovation briefing (MIB) on FreeO2 automatic oxygen titration for chronic obstructive pulmonary disease and respiratory distress syndrome .

    Medtech innovation briefing
    Published
    7 December 2021

  5. Endobronchial nerve ablation for chronic obstructive pulmonary disease (IPG714)

    Evidence-based recommendations endobronchial nerve ablation for chronic obstructive pulmonary disease. This involves destroying (ablating) the nerves on the outside of the airway (endobronchial nerves) to improve breathing.

    Interventional procedures guidance
    Published
    15 December 2021
    View recommendations

    Sections for IPG714

  6. Inhaled therapies for people with COPD and asthma- What is the clinical and cost effectiveness of inhaled therapies (bronchodilators and/or inhaled corticosteroids) in people with both stable COPD and asthma?

    Recommendation ID NG115/3 Question Inhaled therapies for people with COPD and asthma- What is the clinical and cost effectiveness of...

    Research recommendation
    Published
    6 February 2019

  7. Smoking: smoking status of people with long-term conditions (IND156)

    This indicator covers the percentage of patients with any or any combination of the following conditions: CHD, PAD, stroke or TIA, hypertension, diabetes, COPD, CKD or asthma, whose notes record smoking status in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM126

    General practice indicators suitable for use in QOF
    Published
    3 August 2015

  8. Diagnosing COPD: -  What are the characteristics of people diagnosed with COPD as a result of an incidental finding ofemphysema on a CT scan, compared with those diagnosed with symptoms?

    NG115/6 Question Diagnosing COPD: - What are the characteristics of people diagnosed with COPD as a result of an...

    Research recommendation
    Published
    13 February 2019

  9. Mortality: respiratory (IND281)

    This indicator covers under 75 mortality from respiratory disease. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes

    Network / system level indicators
    Published
    30 September 2023

  10. O2matic PRO 100 for optimising oxygen treatment in respiratory conditions (MIB308)

    NICE has developed a medtech innovation briefing (MIB) on O2matic PRO 100 for optimising oxygen treatment in respiratory conditions .

    Medtech innovation briefing
    Published
    11 October 2022

  11. Mepolizumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils ID1237

    In development Reference number: GID-TA10239 Expected publication date:  06 August 2026

    Technology appraisal guidance
    In development

  12. Prophylactic antibiotics for preventing exacerbations:- Which subgroups of people with stable COPD who are at high risk of exacerbations are most likely to benefit from prophylactic antibiotics?

    antibiotics for preventing exacerbations:- Which subgroups of people with stable COPD who are at high risk of exacerbations are most...

    Research recommendation
    Published
    6 February 2019

  13. Smoking: smoking status for people with long-term conditions (IND97)

    This indicator covers the percentage of patients with any or any combination of the following conditions: CHD, PAD, stroke or TIA, hypertension, diabetes, COPD, CKD, asthma, schizophrenia, bipolar affective disorder or other psychoses whose notes record smoking status in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM38

    General practice indicators suitable for use in QOF
    Published
    1 August 2011

  14. Digital technologies to support asthma self-management: early value assessment

    In development Reference number: GID-HTE10063 Expected publication date:  17 April 2026

    Health technology evaluations
    In development

  15. Pulmonary hypertension:- What are the most clinical and cost-effective treatments for pulmonary hypertension in people with COPD?

    clinical and cost-effective treatments for pulmonary hypertension in people with COPD? Any explanatory notes(if applicable) N/A Source...

    Research recommendation
    Published
    13 February 2019